StockLens

Laurus Labs Limited (LAURUSLABS) share price and analysis

LAURUSLABS last traded at ₹2,338.00 (+5.32%) on the NSE. Market cap ₹1,26,325 Cr (Large cap), Pharma & Healthcare sector.

Overall rating: 7.3/10 (Good)

Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.

Strengths of LAURUSLABS

Weaknesses of LAURUSLABS

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)94.4Expensive vs peers37.0–49.3 (sector median 41.1)
Forward P/E66.0Growth expected, but still priceybelow today's P/E (94.4) and near 41
Price / book20.85High6–12 (high ROE allows more)
EPS (TTM)₹24.78Profitableabove ₹0
Return on equity24.0%Strong15%+ (below 10% is weak)
Debt / equity0.42Low debtbelow 1.0 (under 0.5 is great)
Net margin17.1%Healthy10%+ (below 5% is thin)
Operating margin24.1%Strong20%+ strong, below 10% thin
Revenue growth+33.4%Growing well10%+ a year (below 3% is weak)
Profit growth+126.0%Growing well10%+ a year (falling is weak)
Dividend yield0.09%Small payout1.5%+ (none is fine for growth firms)
Current ratio1.31Adequate1.5+ (below 1 is tight)
52W high₹2,488.006% below · near the highprice in the top 40% of its 52-week range
52W low₹917.95Price is 155% above it
50-DMA₹2,090.95Price 11.8% aboveprice above it = short-term uptrend
200-DMA₹1,521.34Price 53.7% aboveprice above it = long-term uptrend
1Y return+133.6%Beat the Nifty 50Nifty 50 did −0.4%
Beta0.22Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider32.0%Moderate stake50%+ shows owner commitment
Institutions35.0%Strong big-investor interest30%+ is strong
Analyst target₹2,156.297.8% downside · 14 analysts8%+ upside

Questions about LAURUSLABS

What is the share price of Laurus Labs Limited (LAURUSLABS) today?

LAURUSLABS last traded at ₹2,338.00 (+5.32% on the day) on the NSE. Its 52-week range is ₹917.95 to ₹2,488.00. Prices are delayed and come from Yahoo Finance.

Is LAURUSLABS a good stock for the long term?

StockLens rates LAURUSLABS 7.3 out of 10 (Good) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: high ROE, uptrend, revenue growth. Concerns: expensive vs peers, cash burn, above analyst targets.

Is LAURUSLABS share overvalued?

LAURUSLABS trades at a P/E of 94.4 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 20.85.

Is LAURUSLABS good for short-term trading?

The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 53.7% above its 200-day average and 14-day RSI is 57.

Which stocks are similar to LAURUSLABS?

Similar Pharma & Healthcare stocks of comparable size include Apollo Hospitals, Zydus Lifesciences, Dr. Reddy's Laboratories, Cipla, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.

About Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Stocks similar to LAURUSLABS

Compare LAURUSLABS with APOLLOHOSP, ZYDUSLIFE, DRREDDY

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.